

AMENDMENT

IN THE CLAIMS:

Please amend the claims as follows:

1-3. (Canceled).

4. (Currently amended) A microfluidized lysate preparation free of dextran made by microfluidizing a slurry of at least one *Leishmania* parasite strain through a chamber and disrupting the leishmania parasite strain with a sudden release of pressure.

5-10. (Canceled).

11. (Original) A kit comprising the microfluidized lysate preparation of claim 4 and directions for determining whether a subject has been exposed to a *Leishmania* parasite or was afflicted with Leishmaniasis.

12. (Currently amended) The kit of claim 11, wherein the *Leishmania* parasite strain is *L. tropica*, *L. mexicana*, *L. guyanensis*, *L. braziliensis*, *L. major*, *L. donovani*, *L. chagasi*, *L. amazonensis*, *L. peruviana*, *L. panamensis*, *L. pifanoi*, *L. infantum*, or *L. aethiopica*.

13-21. (Canceled).

22. (Currently amended) ~~A pharmaceutical composition comprising the~~ The microfluidized lysate preparation of claim 4, and further comprising ~~and~~ a pharmaceutically acceptable stabilizer.

23. (Currently amended) ~~The pharmaceutical composition~~ microfluidized lysate preparation of claim 22, wherein the pharmaceutically acceptable stabilizer is phenol.

24. (Currently amended) ~~The pharmaceutical composition~~ microfluidized lysate preparation of claim 22, wherein the composition is in the form of a liquid.

25. (Currently amended) The ~~pharmaceutical composition~~ microfluidized lysate preparation of claim 22, wherein the composition may be frozen or freeze-dried.

26-28. (Canceled).

29. (Previously added) The microfluidized lysate preparation of claim 4, wherein the microfluidized lysate preparation is heat treated.

30. (Currently amended) The microfluidized lysate preparation of claim 4, wherein the *Leishmania* parasite strain is *L. tropica*, *L. mexicana*, *L. guyanensis*, *L. braziliensis*, *L. major*, *L. donovani*, *L. chagasi*, *L. amazonensis*, *L. peruviana*, *L. panamensis*, *L. pifanoi*, *L. infantum*, or *L. aethiopica*.

31. (New) An immunogenic composition comprising the microfluidized lysate preparation of claim 4.